Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors - PubMed (original) (raw)

Affiliations

PMID: 1974432

Comparative Study

Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors

C L Broekkamp et al. Arzneimittelforschung. 1990 May.

Abstract

trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H- dibenz[2,3:6,7]oxepinol[4,5-c]pyrrolidine maleate (Org 5222) is a new compound with effects on animal behaviour indicating strong antipsychotic potential based on antagonism of dopaminergic and serotonergic effects. The compound inhibits apomorphine-induced climbing behaviour, mouse locomotor activity, rat activity in an open field, shuttle box behaviour in rats, pergolide induced circling in 6-hydroxydopamine(6-OHDA) lesioned rats, serotonin agonist-induced forepaw treading, head shakes and penile erections. The compound is less effective in inducing catalepsy, and antagonising SKF-38393 (tetrahydro- 1-phenyl-1H-3-benzazepine-7,8-diol HCl)-induced circling in 6-OHDA-lesioned rats and it does not induce perioral movements in rats. Based on these data and the neurochemical profile of the compound it was decided that this compound merits clinical investigation in a programme aiming for an effective antipsychotic agent with reduced risks of extrapyramidal side-effects.

PubMed Disclaimer

Cited by

Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.
Frånberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilström B, Shahid M, Wong EH, Svensson TH. Frånberg O, et al. Psychopharmacology (Berl). 2008 Feb;196(3):417-29. doi: 10.1007/s00213-007-0973-y. Epub 2007 Oct 17. Psychopharmacology (Berl). 2008. PMID: 17940749
Asenapine.
Meltzer HY, Dritselis A, Yasothan U, Kirkpatrick P. Meltzer HY, et al. Nat Rev Drug Discov. 2009 Nov;8(11):843-4. doi: 10.1038/nrd3027. Nat Rev Drug Discov. 2009. PMID: 19876039
Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms.
Frånberg O, Marcus MM, Ivanov V, Schilström B, Shahid M, Svensson TH. Frånberg O, et al. Psychopharmacology (Berl). 2009 Jun;204(2):251-64. doi: 10.1007/s00213-008-1456-5. Epub 2009 Feb 7. Psychopharmacology (Berl). 2009. PMID: 19198810
Evaluation of the clinical efficacy of asenapine in schizophrenia.
Minassian A, Young JW. Minassian A, et al. Expert Opin Pharmacother. 2010 Aug;11(12):2107-15. doi: 10.1517/14656566.2010.506188. Expert Opin Pharmacother. 2010. PMID: 20642375 Free PMC article. Review.
The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine.
Cools AR, Prinssen EP, Ellenbroek BA. Cools AR, et al. Psychopharmacology (Berl). 1995 Jun;119(4):428-39. doi: 10.1007/BF02245859. Psychopharmacology (Berl). 1995. PMID: 7480523

Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors - PubMed (original) (raw)